Search Results for "Allergic Conjunctivitis"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Allergic Conjunctivitis. Results 21 to 30 of 47 total matches.
Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
. Drugs for allergic rhinitis and allergic conjunctivitis. Med Lett
Drugs Ther 2021; 63:57.
4. FC Hampel ...
The FDA has approved Ryaltris (Hikma), a fixed-dose
combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase,
and generics) and the corticosteroid mometasone
furoate (Nasonex 24 HR Allergy, and generics), for
treatment of seasonal allergic rhinitis symptoms
in persons ≥12 years old. Ryaltris is the second
intranasal antihistamine/corticosteroid combination
to be approved for this indication; azelastine 0.1%/fluticasone propionate (Dymista, and generics), which
is approved for use in persons ≥6 years old, was the
first. Both products are available...
Med Lett Drugs Ther. 2023 Jan 23;65(1668):12-4 doi:10.58347/tml.2023.1668c | Show Introduction Hide Introduction
Omalizumab (Xolair) for Food Allergy
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
for allergic rhinitis and allergic conjunctivitis. Med Lett
Drugs Ther 2021; 63:57.
3. Peanut allergen powder ...
Omalizumab (Xolair – Genentech), a recombinant
anti-IgE monoclonal antibody FDA-approved for
treatment of allergic asthma, chronic rhinosinusitis
with nasal polyps, and chronic urticaria, has now
also been approved for use in conjunction with food
allergen avoidance to reduce IgE-mediated food
allergic reactions caused by accidental exposure in
patients ≥1 year old. Omalizumab is the first drug to
be approved in the US to reduce allergic reactions to
more than one food. Palforzia, an oral peanut allergen
powder, was approved in 2020 to mitigate allergic
reactions caused by...
Med Lett Drugs Ther. 2024 Apr 1;66(1699):54-6 doi:10.58347/tml.2024.1699b | Show Introduction Hide Introduction
Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025 (Issue 1725)
and allergic conjunctivitis. Med Lett Drugs Ther 2025; 67:49.
2. Approximate WAC for 30 days’ treatment ...
View the Comparison Table: Some Oral Drugs for Allergic Rhinitis
Med Lett Drugs Ther. 2025 Mar 31;67(1725):e55-7 doi:10.58347/tml.2025.1725b | Show Introduction Hide Introduction
Loteprednol 0.25% (Eysuvis) for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • May 17, 2021 (Issue 1624)
surgery, and seasonal allergic conjunctivitis.
Pronunciation Key
Loteprednol etabonate: loe” te pred ...
The FDA has approved loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis – Kala) for
short-term treatment (≤2 weeks) of dry eye disease.
It is the first ocular corticosteroid to be approved for
this indication. Other formulations of loteprednol are
approved for treatment of steroid-responsive ocular
inflammatory conditions, inflammation after ocular
surgery, and seasonal allergic conjunctivitis.
Soft Contact Lenses
The Medical Letter on Drugs and Therapeutics • Jul 27, 1990 (Issue 823)
wearers develop chronic allergic conjunctivitis with symptoms of eye irritation, discharge, and decreasing ...
Soft contact lenses have been in use for more than 20 years. Since the last Medical Letter review (vol. 24, page 109, 1982), new products have been developed, and some problems have emerged.
Cyclosporine Ophthalmic Emulsion (Verkazia) for Vernal Keratoconjunctivitis
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
and allergic conjunctivitis. Med Lett
Drugs Ther 2021; 63:57.
3. JS Mehta et al. Diagnosis, management ...
The FDA has approved Verkazia (Santen), a 0.1%
ophthalmic emulsion formulation of the calcineurin
inhibitor cyclosporine, for treatment of vernal
keratoconjunctivitis (VKC). Verkazia is the first
product to be approved in the US for this indication.
Med Lett Drugs Ther. 2023 May 1;65(1675):70-2 doi:10.58347/tml.2023.1675d | Show Introduction Hide Introduction
A Topical Prostaglandin for Glaucoma
The Medical Letter on Drugs and Therapeutics • Nov 08, 1996 (Issue 987)
outflow, but they may cause conjunctival
hyperemia and, with chronic use, can cause allergic ...
Lantaoprost, a prostaglandin F2-alpha analog, has been approved by the FDA for topical treatment of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension refractory to other drugs.
Drugs for Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • Dec 02, 2019 (Issue 1586)
macular degeneration (AMD), bacterial
conjunctivitis, and dry eye disease. Allergic conjunctivitis ...
This issue includes reviews of drugs for glaucoma,
age-related macular degeneration (AMD), bacterial
conjunctivitis, and dry eye disease. Allergic conjunctivitis
is reviewed in a separate issue.
In Brief: Omlyclo — An Omalizumab Biosimilar Interchangeable with Xolair
The Medical Letter on Drugs and Therapeutics • Jun 09, 2025 (Issue 1730)
and
Xolair for treatment of chronic spontaneous urticaria.
FDA approval of Omlyclo for allergic asthma ...
Omlyclo (omalizumab-igec; Celltrion), a biosimilar
product interchangeable with the recombinant anti-IgE monoclonal antibody Xolair, has been approved by
the FDA for same indications as Xolair (see Table 1).
Omlyclo is the first Xolair biosimilar to be approved in
the US.
Med Lett Drugs Ther. 2025 Jun 9;67(1730):95-6 doi:10.58347/tml.2025.1730f | Show Introduction Hide Introduction
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024 (Issue 1716)
.
Hypersensitivity reactions including rash, allergic
conjunctivitis, and anaphylaxis have been reported ...
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations in the
emergency department is not discussed here.
Med Lett Drugs Ther. 2024 Nov 25;66(1716):185-92 doi:10.58347/tml.2024.1716a | Show Introduction Hide Introduction